PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma

Journal: Nature Communications

Published: 2020-05-01

DOI: 10.1038/s41467-020-15959-6

Affiliations: 10

Authors: 18

Go to article
Institutions Share
Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, United States of America (USA) 0.42
Division of Hematology-Oncology, VU, United States of America (USA) 0.14
Department of Systems Biology, MD Anderson Cancer Center, United States of America (USA) 0.11
Institute of Biosciences and Technology (IBT), TAMU, United States of America (USA) 0.11
Department of Biostatistics, MD Anderson Cancer Center, United States of America (USA) 0.06
Department of Neuro-Oncology, MD Anderson Cancer Center, United States of America (USA) 0.06
Department of Epigenetics and Molecular Carcinogenesis, MD Anderson Cancer Center, United States of America (USA) 0.06
Department of Urology at Renji Hospital, SJTU, China 0.03
Vanderbilt-Ingram Cancer Center (VICC), VU, United States of America (USA) 0.03

Return

Except where otherwise noted © 2020 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER